Investigating the risk of cerebral amyloid angiopathy from blood transfusions
Official title: Possible transfusion transmitted cerebral amyloid angiopathy: evaluation of transmission of Aβ using the RADAR repository
Funded at Vitalant · NIH-10954688 · Data updated 2026-11-12
This study is looking into whether getting a blood transfusion from someone who later develops cerebral amyloid angiopathy (CAA) could increase your chances of having the same condition, which can cause serious brain issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vitalant NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $131,250 |
| NIH project number | 1R21HL175170-01 |
| Project ID | NIH-10954688 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have received blood transfusions and are at risk for developing cerebral amyloid angiopathy.
✕Less likely to help
Patients who have not received blood transfusions or those without risk factors for CAA may not benefit from this research.
What this research studies
This research explores the potential transmission of cerebral amyloid angiopathy (CAA) through blood transfusions. It focuses on the aggregation of amyloid beta (Aβ) in the brain, which can lead to severe complications such as spontaneous intracerebral hemorrhage. By analyzing data from blood transfusion records, the study aims to determine if patients who received blood from donors later diagnosed with CAA are at increased risk of developing this condition themselves. The methodology involves a retrospective cohort analysis using a large database to identify patterns and risks associated with blood transfusions.
Why it matters
Potential benefit: If successful, this research could lead to improved safety protocols for blood transfusions, potentially reducing the risk of CAA in patients.
How similar studies have gone: Previous research has indicated potential risks associated with blood transfusions and prion-like transmission, suggesting that this area of investigation is both relevant and necessary.
Where this research is happening
-
Vitalant
Scottsdale, United States Active
Researchers
- Principal investigator: Busch, Michael Paul — Vitalant
- Study coordinator: Busch, Michael Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.